Novel tissue-agnostic biomarker approaches could improve response to immunotherapy
Several studies describe pan-cancer approaches utilising the latest technology for better patient selection and outcomes
First trial evidence supports minimal residual disease-guided adjuvant immunotherapy in bladder cancer
In the IMvigor011 trial, ctDNA positivity was reported to be strongly predictive of adjuvant immunotherapy benefit in muscle-invasive bladder cancer
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
New artificial intelligence-based biomarkers offer early insight into treatment response
Findings from four studies provide further evidence on the potential of AI-driven pathology, imaging and multiomic data to guide clinical decision-making
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
Is it time to shift supportive care toward digital-assisted approaches?
Recent findings show digital tools have the potential to improve the monitoring of symptoms and psychological aspects, but they should be integrated within routine clinical practice
Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer
Data from the ELEVATE and ALINA studies highlight the gains provided by adjuvant ALK therapy in patients with ALK-positive disease
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Survival improvements observed with first-line antibody–drug conjugates in triple-negative breast cancer
TROP2-targeted ADCs, sacituzumab govitecan and datopotamab deruxtecan, meet their primary endpoints in phase III trials
Innovative strategies lead to mixed benefits for rare cancers
Positive findings are presented for advanced Merkel-cell carcinoma plus phaeochromocytoma and paragangliomas, while negative findings are equally important to guide future research